若生智能
Drug Database
VA

Varicella zoster vaccine (Sky Varicella / NBP608 / SKYVaricella)

✓ Approved

SK Chemicals · 疫苗 · 疫苗

什么是 Varicella zoster vaccine？

Varicella zoster vaccine 是一种疫苗，由SK Chemicals研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection、Subcutaneous Injection。

药物档案

商品名Sky Varicella, NBP608, SKYVaricella
公司SK Chemicals
药物类别疫苗, 大分子
给药途径Injectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, SK Chemicals

治疗适应症

Varicella zoster vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsVaricella zoster virus infection✓ Approved

相关研究文献

PubMedFrontiers in immunology2026-08-05

Effectiveness of varicella vaccine during a varicella outbreak in a Chinese senior high school: a retrospective cohort study.

Xu Nani N, Wu Liting L, Deng Xuan X, Shu Xin X et al.

To evaluate the vaccine effectiveness (VE) of single-dose and two-dose varicella vaccine (VarV) among senior high school students during a varicella outbreak in China, and provide recommendations for vaccination strategy optimization. A retrospective cohort study was conducted among students in a senior high school in China during a varicella outbreak from July 23 to November 8, 2024. The history of varicella disease, the immunization history of VarV and the incidence during the outbreak among all students in the school were surveyed. Kaplan-Meier methods were used to estimate the cumulative varicella-free survival rate among students with different immunization histories during the outbreak, and the log-rank test was used to compare the survival curves across the five groups. VE was calculated based on attack rates among students with different vaccination doses and intervals since last vaccination. Post-exposure vaccination VE was also assessed. Logistic regression analysis was performed to identify factors associated with varicella infection during the outbreak, and odds ratio (OR) and 95% confidence interval (95% CI) were calculated. Among the 1,862 students present during the outbreak, the overall varicella attack rate was 6.29%. Kaplan-Meier analysis showed significant differences in cumulative varicella-free survival among the different immunization groups (χ² = 297.913, df = 4, P < 0.001). Single-dose varicella vaccine (VarV) coverage was 28.24% (475/1682), and two-dose coverage was 66.23% (1114/1682). Compared with unvaccinated individuals, VE with 95% CI was 32.14% (-54.37%- 70.17%) for 1-dose recipients and 94.74% (88.62%-97.57%) for 2-dose recipients. Among 1-dose recipients, VE was 90.48% (17.22%-98.90%) and 18.68% (-86.86%- 64.61%) for those with an immunization interval ≤10 years and >10 years, respectively. Among 2-dose recipients, VE was 95.94%(90.69%-98.23%) and 92.89%(83.87%-96.87%) for those with an immunization interval ≤6 years and >6 years, respectively. Logistic regression showed that male students had a higher risk of varicella than female students; prior receipt of two doses of VarV significantly reduced the risk of infection; and the risk increased by 1 year for each additional year between the last immunization and exposure to the index case. The VE of post-exposure vaccination was 90.15% (68.53%-96.92%) among unvaccinated students and 94.88% (89.47%-97.51%) among students who had previously received 1 dose. A single dose of varicella vaccine provides limited long-term protection among high school students, whereas a two-dose regimen offers robust and sustained effectiveness. Routine catch-up vaccination and timely post-exposure vaccination are recommended for the effective control of varicella outbreaks in school settings.

PMID 42553282
阅读全文 →
PubMedJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2026-08-05

Atopic dermatitis is associated with herpes zoster in adults - A matched cohort study using electronic health records data in England.

Schober Anna K AK, Langan Sinéad M SM, Williams Hywel C HC, Forbes Harriet H et al.

Some atopic dermatitis (AD) treatments have been linked to an increased risk of herpes zoster (HZ). Limited evidence suggests an independent association between atopic dermatitis and herpes zoster. The study aimed to investigate the association between atopic dermatitis and herpes zoster in the UK and to explore the role of treatments in this relationship. We conducted a matched cohort study using routinely collected primary care data from the UK Clinical Practice Research Datalink (CPRD) Aurum database (1997-2023) and applied Cox regression models. Age, behavioral factors, several comorbid diseases and different treatment exposures were included as covariates. Individuals with atopic dermatitis had an adjusted hazard ratio of 1.28 (95% CI: 1.27-1.29) for HZ. Adjustments for different definitions of oral corticosteroid exposure as well as other traditional immunosuppressants led to minimal reductions in the association. The risk of herpes zoster increased with AD severity (aHR for mild AD: 1.22 [95% CI: 1.20-1.23]; aHR for moderate AD: 1.28 [95% CI: 1.27-1.30]; aHR for severe AD: 2.33 [95% CI: 2.22-2.45]). The risk of HZ is increased in individuals with atopic dermatitis, independent of comorbidities and the use of oral corticosteroids or immunosuppressants. This elevated baseline risk is particularly relevant because herpes zoster is also a known adverse effect of newer therapies such as Janus kinase (JAK) inhibitors. These findings may inform vaccination guidelines.

PMID 42552854
阅读全文 →
PubMedFrontiers in global women's health2026-08-05

Awareness, factual knowledge, attitudes, and acceptability of human papillomavirus vaccination among adult women in Palestine: a cross-sectional study.

Amro Alhareth M AM, Safadi Leen M LM, Fahoum Shahd R SR, Deeb Salahaldeen S et al.

Human papillomavirus (HPV) is a major preventable cause of cervical cancer, yet awareness and uptake of HPV vaccination remain suboptimal in many settings. Evidence regarding women's HPV-related awareness, factual knowledge, and vaccine acceptability in Palestine remains limited. This study assessed awareness, factual knowledge, attitudes, self-reported uptake, willingness, and perceived barriers related to HPV infection and HPV vaccination among adult women in Palestine. A cross-sectional online survey was conducted between October 2025 and February 2026 among women aged ≥18 years residing in Palestine. The questionnaire assessed sociodemographic characteristics, HPV and HPV vaccine awareness, factual knowledge, attitudes, vaccine uptake, willingness to receive or recommend vaccination, and perceived barriers. A 12-item factual knowledge score was calculated, and higher factual knowledge was defined as ≥7 correct responses. Descriptive statistics, subgroup analyses, and multivariable logistic regression were performed. Among 424 adult women included in the final analysis, 220 (51.9%) had heard of HPV and 146 (34.4%) had heard of the HPV vaccine. The mean factual knowledge score was 4.03 ± 2.72 out of 12, and 90 participants (21.2%) had higher factual knowledge. Self-reported HPV vaccine uptake was low (13.0%), whereas willingness to receive the vaccine was higher (55.2%). Lack of awareness (55.8%) and concern about vaccine safety (22.8%) were the most frequently reported barriers among unvaccinated women. In expanded adjusted analyses, prior HPV awareness, prior HPV vaccine awareness, and more supportive HPV-vaccination attitudes were independently associated with higher factual knowledge. Higher factual knowledge and supportive attitudes were associated with self-reported vaccine uptake, while willingness among unvaccinated women was most strongly associated with supportive vaccination attitudes. Adult women in Palestine demonstrated limited HPV-related awareness and low factual knowledge, together with low self-reported HPV vaccine uptake. The gap between willingness and uptake, combined with the predominance of awareness and safety concerns as reported barriers, suggests a need for culturally appropriate education, provider-led counseling, and improved access to reliable HPV vaccine information. Findings should be interpreted cautiously given the cross-sectional design and online convenience sampling.

PMID 42553322
阅读全文 →
PubMedClinical kidney journal2026-08-05

Lipid parameters but not inflammatory indices predict hepatitis B vaccine responses in hemodialysis patients.

Ekici Hilal H, Mirza Arzu A, Baltacı Sevgi S, Eren Davut D et al.

Hepatitis B virus (HBV) vaccination is essential in hemodialysis (HD) populations, yet seroprotection remains suboptimal. Inflammation-related hematologic indices are frequently used in clinical practice, but their ability to predict HBV vaccine response in HD patients is uncertain. We evaluated clinical and laboratory determinants of HBV vaccine response, with a focus on lipid-derived indices and inflammatory ratios. In this multicenter retrospective study, adult HD patients followed between 2015 and 2025 who received at least three doses of HBV vaccine and had available anti-HBs measurements were included (n = 341). Vaccine response was defined as anti-HBs ≥10 IU/L; non-response as <10 IU/L. Neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR), monocyte-to-lymphocyte (MLR), neutrophil percentage-to-albumin ratio (NPAR), and lipid ratios (TG/HDL, TC/HDL, LDL/HDL) were calculated. Additional analyses using percentile-based categorization of NPAR confirmed the absence of a significant association with vaccine response. Multivariable logistic regression and receiver operating characteristic analyses were performed. After the primary vaccination series, seroprotection was 77.4% and increased to 88.6% after revaccination/boosters; it declined to 78.3% at 1 year and 69.2% at 2 years. Non-responders were older and had higher triglyceride levels and lower HDL cholesterol levels. In contrast, inflammatory indices (NLR, PLR, MLR, and NPAR) did not differ significantly between groups. These indices also demonstrated limited discriminative ability for predicting vaccine response. In multivariable analysis, HDL cholesterol remained positively associated with vaccine response [odds ratio (OR): 1.046, 95% confidence interval (CI): 1.006-1.086, P = .022], and triglyceride levels were negatively associated with vaccine response (OR: 0.992, 95% CI: 0.984-0.999, P = .024). The TG/HDL ratio showed borderline statistical significance (OR: 1.235, 95% CI: 0.983-1.551, P = .070), suggesting a potential but limited contribution to vaccine response prediction. In HD patients, hematologic inflammatory indices were not informative for HBV vaccine response, whereas an atherogenic lipid profile-particularly lower HDL and higher triglycerides-showed a consistent association. Lipid parameters may support risk stratification and tailored post-vaccination monitoring strategies.

PMID 42553896
阅读全文 →
PubMedHIV/AIDS (Auckland, N.Z.)2026-08-05

From Denial to Near Blindness: Overcoming Herpes Zoster Ophthalmicus in a Rural Ugandan Man with HIV and Alcoholism.

Okongo Benson B, Amuge Gladys G, Adong Ruth Lucy RL, Okengo Anthony O AO et al.

In remote Ugandan settings, HIV care retention remains poor among men and pastoralists. Despite progress toward UNAIDS 95-95-95 targets, structural barriers, geographic isolation and stigma continue to undermine long-term retention. In 2022, a male pastoralist in his early forties with heavy alcohol use presented to a rural health center in Karamoja with fever and weight loss, and was diagnosed with HIV. He declined antiretroviral therapy (ART) believing the drugs were "poisonous" and was lost to follow-up for 48 months. He re-presented in March 2026 with a one-year history of a scaly, pruritic lesion on his right hand extending to the face and neck, unresponsive to antifungal creams. Two days prior, he developed an acutely painful vesicular eruption in the right V1 trigeminal distribution, along with oropharyngeal candidiasis. CD4 count was 120 cells/μL and urine TB LAM was positive, indicating disseminated tuberculosis. While LAM is highly suggestive and warrants immediate empirical treatment, definitive diagnosis of dissemination ideally requires clinical and radiological correlation. He was treated with oral acyclovir (800 mg five times daily for 10 days), topical acyclovir, ibuprofen, intensive-phase anti-TB therapy, and fluconazole (200 mg daily for 14 days). ART was deferred for two weeks to manage acute opportunistic infections and monitor for IRIS. At two weeks, the zoster lesions had crusted, oral candidiasis cleared, and pain reduced to 2/10. ART was initiated on day 14 with village health team support. At three months, he remained adherent with no new opportunistic infections. Delayed ART initiation caused years of preventable suffering. This case highlights the urgent need in low-income settings for community re-engagement strategies, integrated HIV/co-infection screening, point-of-care diagnostics, and culturally tailored care. As the patient stated: "I was sick, and now I am well. The science of HIV treatment is a miracle, and I am living proof.".

PMID 42553801
阅读全文 →
PubMedInternal medicine journal2026-08-05

Critical role of vaccination in preventing severe coronavirus disease 2019: perspectives from clinical outcomes in an Australian kidney transplant recipient cohort.

Tharmaraj Dhakshayini D, Naidu Paayal P, Baptista Mohana M, McBride Sarah S et al.

Kidney transplant recipients (KTRs) disproportionately experience severe COVID-19 infections. We previously identified concern regarding vaccine-induced rejection as a barrier to vaccine uptake. This study assesses COVID-19 vaccine uptake, infection outcomes and allograft rejection in KTRs during the delta and omicron waves (BA.1/BA.2). This cohort study included all adult KTRs with a functioning allograft at 22 March 2021 at our centre. KTR and vaccination-related risk factors for the primary outcome of severe COVID-19 infection (requiring hospitalisation) and the secondary outcomes of death and all COVID-19 infections were assessed using Cox proportional hazards models. Rejection risk following infection/vaccination was also assessed. Of the 986 included KTRs, there were 333 (33.8%) COVID-19 infections, 79 (23.7%) severe infections and 13 deaths (n = 13/333, 3.9%). Vaccine number was the most significant modifiable predictor of severe infection (adjusted hazards ratio, per additional dose, 0.5; 95% confidence interval, 0.40-0.65, P < 0.001) and death. While older age also predicted severe infection and death, lower estimated glomerular filtration rate, history of diabetes and previous allograft rejection predicted severe infection. Male gender was the only predictor of all infections. Mycophenolate dose, prednisolone use and vaccine type did not predict infection or severe disease. Infections and vaccinations did not increase the risk of rejection. KTRs should be encouraged to be optimally vaccinated to prevent severe disease and can be reassured about the low risk of allograft rejection. Risk factors that compound the state of immunocompromise and severe COVID-19 infections should prompt vigilance and targeted interventions to mitigate these risks.

PMID 42554002
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Varicella zoster vaccine